Fourth Annual CUA Astellas Research Grant Recipients Announced
MARKHAM, ON, Oct. 5, 2015 /CNW/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. (Astellas) are pleased to announce the recipients of the fourth annual CUA Astellas Research Grant Program.
In 2012, Astellas pledged $750,000 over a period of five years to the program, which supports Canadian peer-reviewed urology research, with the ultimate goal of improving patient care. This year, eight research proposals were received and reviewed by an independent committee comprised of nine members. The 2015 CUA Astellas Research Grant Program recipients are:
"The role of succinate in the treatment of voiding dysfunction associated with metabolic syndrome"
Lady Davis Institute, Jewish General Hospital, McGill University
"The Impact of urinary symptoms on gait: Is urinary urgency a source of diverted attention leading to gait changes and falls in older people with overactive bladder?"
University of Alberta, Department of Medicine, Division of Geriatric Medicine
"Tissue Engineering of a Functional Tunica Albuginea for the Correction of Penile Curvature"
University of Laval
"The Canadian researchers and members of the CUA awarded with CUA-Astellas research grants have had exceptional hypotheses and study proposals regarding important clinical and translational areas in functional urology. This area of urology encompasses many subspecialties, as can be seen by the type of study proposals being awarded," said Dr. Jonathan Izawa, Chair of the CUASF Scientific Council. "Last year, the grants also included randomized, prospective trials ranging from antibiotic prophylaxis in infants megaureter to a placebo controlled trial for ureteral stent pain in patients with urolithiasis. All of these studies have the potential to make significant contributions for our urological patients. We are very grateful for this support from Astellas."
"We are excited to continue our sponsorship of the CUA Astellas Research Grant Program in support of peer-reviewed urology research," said Michael Tremblay, president, Astellas Pharma Canada. "This innovative research has the potential to lead to important discoveries which will allow those suffering to spend more quality time with their loved ones and can ultimately improve the quality of life for Canadian patients."
Proposals for the 2016 CUA Astellas Research Grant Program are now being accepted. The submission deadline is January 8th, 2016. Additional details regarding the eligibility criteria and application process can be found on both the CUA and Astellas websites:
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.
The goals of the CUA are to:
- To foster and promote excellence in urologic practice through education and research.
- To provide leadership in promoting evidence based clinical practice through the development of practice guidelines.
- To foster and promote life-long learning by Canadian urologists through continuous professional development.
- To provide leadership in public education for urologic diseases.
- To represent Canadian urology in developing and fostering partnerships while maintaining the highest educational and ethical standards.
- To represent the Canadian urologic community in relationships with national and international medical societies.
More information about CUA can be found at www.cua.org
About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on five therapeutic areas – Urology, Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.
For further information: Tal Erdman, Canadian Urological Association, (514) 395-0376, email@example.com; Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., (905) 946-5621, Michelle.Reale@astellas.com